Semax and Selank for ADHD: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtags, this creator is describing a self-directed experiment: they're already on Effexor (venlafaxine) for what they're framing as ADHD-adjacent symptoms, and they've decided to layer in two Russian peptides, Semax and Selank, to chase better focus and mental clarity. The #greymarket hashtag is honest, at least. This is the cognitive biohacking genre at its most unfiltered: pharmaceutical dissatisfaction meets peptide influencer culture, served with a lab emoji. The implicit claim is that Semax and Selank can do something meaningful for ADHD symptom management that an FDA-approved medication isn't doing. That's a significant claim, and the evidence base behind it deserves more scrutiny than a TikTok caption provides.

What does the science actually show?

Semax is a synthetic heptapeptide derived from ACTH(4-7), developed in Russia in the 1980s. The most credible published work comes from Dolotov et al. (2006, Journal of Neurochemistry), showing that Semax increases BDNF and its receptor TrkB in rat brain tissue. There are small Russian clinical trials, including one by Kaplan et al. (2015, CNS Drug Reviews), suggesting cognitive benefits in stroke patients. The ADHD angle? Essentially absent from peer-reviewed literature. Selank is a synthetic analog of tuftsin with claimed anxiolytic properties. Skrebitsky et al. (2014, Experimental Brain Research) documented synaptic plasticity effects in rodents. Human trial data is sparse, mostly unpublished Russian registry studies. Neither peptide has completed Phase III trials outside Russia. Neither has FDA approval. Dosing protocols circulating online are not derived from controlled human studies.

Where does the social media noise diverge from clinical reality?

The biohacking community treats Semax and Selank as established cognitive tools. They are not. The influencer pipeline here works like this: Russian pharmacology research (real, but limited) gets translated into English-language forums, amplified by peptide vendors, and eventually reaches TikTok as confident self-experimentation content. The actual published human data for Semax in cognitive applications involves stroke recovery populations, not healthy adults with ADHD. Extrapolating that to a person already on an SNRI is a leap the research does not support. Adding an uncharacterized peptide to venlafaxine without clinical supervision also carries real serotonergic interaction risk that nobody in the #peptok space seems to be discussing. The framing of "praying for clarity" reads as self-aware, but the behavior is still combining an unscheduled grey-market peptide with a regulated antidepressant without medical oversight.

What should you actually know?

If Effexor isn't addressing ADHD symptoms adequately, the evidence-based next step is a prescriber conversation, not a peptide stack sourced from a grey market. Venlafaxine is not a first-line ADHD medication to begin with. It's sometimes used off-label when stimulants aren't tolerated, but if symptom control is insufficient, the clinical pathway is to reassess the medication choice, not to supplement with compounds that have no peer-reviewed ADHD efficacy data in humans. Semax and Selank are not classified as controlled substances in the US, which is why they circulate openly, but that legal grey area does not confer safety or efficacy. Sourcing purity is a real problem: a 2022 analysis by the Peptide Science journal flagged significant concentration variability in commercially available research peptides. This is not a stack to run casually, and certainly not without medical supervision.